Personalized Ultrasonic Brain Stimulation for Depression
Personalized Ultrasonic Brain Stimulation for Depression: A Pilot Study of Target Engagement and Mood Effects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Brian J Mickey, MD, PhD
- Phone Number: 801-587-0159
- Email: brian.mickey@utah.edu
Study Contact Backup
- Name: Jan Kubanek, PhD
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-65, any gender
- Primary diagnosis of major depressive disorder or bipolar disorder
- Current moderate-to-severe depressive episode, without psychotic features, lasting at least 2 months
- Self-rated 16-item Quick Inventory of Depressive Symptomatology (QIDS) total score > 10
- Stated willingness to comply with all study procedures and avoid changes to psychiatric treatments (medications, psychotherapy) for the duration of the study
- For females of reproductive potential: negative pregnancy test or use of highly effective contraception for at least 1 month prior to baseline; agreement to use such a method throughout the study
- Capacity to provide informed consent; provision of a signed and dated consent form
Exclusion Criteria:
- History of serious brain injury or other neurologic disorder
- Poorly managed general medical condition
- Pregnant or breast feeding
- Implanted device in the head or neck
- MRI intolerance or contraindication
- Brain stimulation (e.g., ECT, TMS, VNS) in the past month
- Suicidal ideation (Columbia Suicide Severity Rating Scale screen item #2, past month)
- Lifetime history of a serious suicide attempt
- Moderate-to-severe substance use disorder (past 3 months)
- Obsessive compulsive disorder (past month)
- Posttraumatic stress disorder (past month)
- Schizophrenia-spectrum disorder (lifetime)
- Neurocognitive disorder (past year)
- Personality disorder as a current focus of treatment
- Clinically inappropriate for participation in the study as determined by the study team
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Active stimulation
Personalized low-intensity transcranial focused ultrasound stimulation of deep brain target (subgenual cingulate or alternative targets)
|
Diadem prototype device delivers personalized low-intensity transcranial focused ultrasound stimulation
|
|
Sham Comparator: Sham stimulation
Personalized low-intensity transcranial focused ultrasound stimulation of lateral ventricle
|
Diadem prototype device delivers personalized low-intensity transcranial focused ultrasound stimulation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Target engagement: MRI quantification of brain activation
Time Frame: 1 day at MRI study visit
|
Blood oxygenation level dependent (BOLD) or arterial spin labeling (ASL) response to active versus sham stimulation
|
1 day at MRI study visit
|
|
Target engagement: MRI quantification of brain connectivity
Time Frame: 1 day at MRI study visit
|
Resting functional connectivity of target in response to active versus sham stimulation
|
1 day at MRI study visit
|
|
Change in depression severity measured with the HDRS-6
Time Frame: 1 day and 7 days after stimulation
|
6-item Hamilton Depression Rating Scale (HDRS-6), range 0-22, higher score represents greater depression
|
1 day and 7 days after stimulation
|
|
Change in Sadness scale of PANAS-X
Time Frame: 1 hour, at stimulation study visit
|
Positive and Negative Affect Schedule Extended (PANAS-X), range 0-100, higher score represents greater sadness
|
1 hour, at stimulation study visit
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Brian J Mickey, MD, PhD, University of Utah
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB_00148802
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.